It is tempting to speculate that Enzalutamide treatment enforces the co-regulation of SK3/Orai1 in LNCaP cells and allows a more intensive study of key determinants mediating the SK3–Orai1 interplay in this prostate cancer cell line. Here, KCNN3 is linked to prostate carcinoma.